When was ADARx Pharmaceuticals founded?

ADARx Pharmaceuticals was founded in 2019 and raised its 1st funding round 1 year after it was founded.

Where is ADARx Pharmaceuticals located?

ADARx Pharmaceuticals is headquartered in San Diego, United States. It is registered at San Diego, California.

Who is the current CEO of ADARx Pharmaceuticals?

Zhen Li of ADARx Pharmaceuticals. They have also founded 1 company.

How many employees does ADARx Pharmaceuticals have?

As of Aug 31, 2026, the latest employee count at ADARx Pharmaceuticals is 102.

Is ADARx Pharmaceuticals a funded company?

ADARx Pharmaceuticals is a funded company, having raised a total of $353M across 7 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Jan 24, 2020.

How much is ADARx Pharmaceuticals worth?

The latest valuation of ADARx Pharmaceuticals is $***** as of Aug 09, 2023.

When was the latest funding round of ADARx Pharmaceuticals?

ADARx Pharmaceuticals' latest funding was a $***** Series C round on Aug 02, 2023, with participation from 16 investors. Its primary sector is Genomics. In United States, the Genomics sector has seen $2.25B in funding in 2026 to date.

Where does ADARx Pharmaceuticals rank among its competitors?

ADARx Pharmaceuticals ranks 4th amongst 68 active competitors, of which 21 are funded. It stands 1st in terms of total funding among its competitors. The most recent competitor to raise funding was Senti Bio, which secured $40M in May, 2026.

Who are the top competitors of ADARx Pharmaceuticals?

ADARx Pharmaceuticals' top competitors include Senti Bio, CRISPR Therapeutics and Geninus. Among them, Senti Bio secured the most recent funding round in May, 2026.

ADARx Pharmaceuticals - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of genetic therapeutic solutions to edit single point mutations on RNA transcripts. The company has genetic therapeutics that precisely target RNA transcripts to enable the production of desired proteins. It helps in the nucleotide sequence specified in the genomic template that is modified to produce a different nucleotide sequence in the transcript.

Website: www.adarx.com/
Email ID: *****@adarx.com
Registered Address: San Diego, California

Key Metrics

Founded Year

2019

Location

San Diego, United States

Stage

Series C

Total Funding

$353M in 7 rounds

Latest Funding Round

Series C, Aug 02, 2023, $*****

Post Money Valuation

$***** as on Aug 09, 2023

Investors

Orbimed & 18 more

Ranked

4^th among 68 active competitors

Employee Count

102 as on Aug 31, 2026

Similar Companies

Senti Bio & 83 more

View ADARx Pharmaceuticals' full profile

ADARx Pharmaceuticals is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
ADARX PHARMACEUTICALS INC CIN: 844145188 , United States, Active		-	67 (As on Dec 31, 2024)	-

ADARx Pharmaceuticals has raised a total funding of $353M over 7 rounds. Its first funding round was on Jan 24, 2020. Its latest funding round was a Series C round on Aug 02, 2023 for $*****. 16 investors participated in its latest round. ADARx Pharmaceuticals has 19 institutional investors.

Here is the list of recent funding rounds of ADARx Pharmaceuticals:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Aug 02, 2023	5758753	Series C	9570831	4182479	7203605	9253040
Jan 20, 2023	4886196	Series C	7251124	8065606	7699969	Orbimed & 3 more
Jul 30, 2021	3081077	Series C	7117593	9269227	SR One & 1 more	Lilly Asia Ventures & 1 more

Access funding benchmarks and valuations. Sign up today!

View details of ADARx Pharmaceuticals's funding rounds and investors

The founders of ADARx Pharmaceuticals is Zhen Li. Zhen Li is the CEO of ADARx Pharmaceuticals.

Here are the details of ADARx Pharmaceuticals' key team members:

Zhen Li: Co-Founder & CEO of ADARx Pharmaceuticals.
Contact Info: 1 email address

View details of ADARx Pharmaceuticals's Founder profiles and Board Members

ADARx Pharmaceuticals' employee count trend

ADARx Pharmaceuticals has 102 employees as of Aug 26. Here is ADARx Pharmaceuticals's employee count trend over the years:

Employee count trend for ADARx Pharmaceuticals

Uncover ADARx Pharmaceuticals' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of ADARx Pharmaceuticals include Senti Bio, CRISPR Therapeutics and Geninus. Here is the list of Top 10 competitors of ADARx Pharmaceuticals, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, Leaps by Bayer & 30 others	72/100
2nd	CRISPR Therapeutics 2013, Basel (Switzerland), Public	Developer of solutions for treating human genetic diseases by using genome editing technology	$127M	Celgene, New Leaf Venture Partners & 10 others	63/100
3rd	Geninus 2018, Seoul (South Korea), Public	Developer of genomic-based disease prevention platform	$13.3M	IMM Investment, Korea Investment Partners ... & 5 others	61/100
4th	ADARx Pharmaceuticals 2019, San Diego (United States), Series C	Developer of genetic therapeutic solutions to edit single point mutations on RNA transcripts	$353M	Bain Capital Life Sciences, T. Rowe Price ... & 17 others	58/100
5th	Genprex 2009, Austin (United States), Public	Developer of therapeutics to treat cancer at molecular level	$3.11M	Inception Capital Management, TiE ScaleUp ... & 1 others	56/100
6th	Bota 2019, Lafayette (United States), Series B	Developer of AI-based platform for enzyme and strain engineering	$100M	Sequoia Capital China, BASF & 9 others	55/100
7th	Avectas 2011, Dublin (Ireland), Series C	Provider of non-viral cell engineering technology platform for drug discovery	$33.5M	EIC Fund, Europa & 1 others	54/100
8th	Modular Genetics 2000, Woburn (United States), Series B	Developer of a proprietary, automated system for gene engineering and molecular biology	$8.9M	MassVentures, America’s Seed Fund & 2 others	52/100
9th	GeneScience Pharmaceuticals 1996, Changchun (China), Series B	Provides genetically engineered pharmaceuticals products	-	Haitong Bank, China Huarong Asset Management ... & 3 others	51/100
10th	Poseida Therapeutics 2015, San Diego (United States), Acquired	Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies	$324M	Fidelity Investments, Longitude Capital & 12 others	50/100